Printer Friendly

Restless Legs Syndrome Pipeline Review, H1 2019 Report.

M2 PRESSWIRE-August 8, 2019-: Restless Legs Syndrome Pipeline Review, H1 2019 Report

(C)1994-2019 M2 COMMUNICATIONS

RDATE:08082019

The "Restless Legs Syndrome - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Restless Legs Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 2 and 2 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Companies Mentioned

- Axim Biotechnologies Inc

- Bioprojet SCR

- Hisamitsu Pharmaceutical Co Inc

- Merz Pharma GmbH & Co KgaA

- Omeros Corp

- Relmada Therapeutics Inc

- Serina Therapeutics Inc

- Vifor Pharma Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/olc3fe

CONTACT:

ResearchAndMarkets.com,

Laura Wood, Senior Press Manager

press@researchandmarkets.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.com on the world wide web. Inquiries to info@m2.com)).
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Presswire
Article Type:Report
Date:Aug 8, 2019
Words:459
Previous Article:Global ECG Equipment & Management Systems Market 2019-2025: Analysis by Type, End-use, and Region.
Next Article:Microscopic Polyangiitis (MPA) Pipeline Review, H1 2019 Report Featuring Celltrion, ChemoCentryx, InflaRx, Teijin Pharma.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters